X4 Pharmaceuticals Statistics
Share Statistics
X4 Pharmaceuticals has 5.79M
shares outstanding. The number of shares has increased by 0.49%
in one year.
Shares Outstanding | 5.79M |
Shares Change (YoY) | 0.49% |
Shares Change (QoQ) | 0.82% |
Owned by Institutions (%) | 49.7% |
Shares Floating | n/a |
Failed to Deliver (FTD) Shares | 318 |
FTD / Avg. Volume | 0.27% |
Short Selling Information
The latest short interest is 312.3K, so 5.4% of the outstanding
shares have been sold short.
Short Interest | 312.3K |
Short % of Shares Out | 5.4% |
Short % of Float | 5.47% |
Short Ratio (days to cover) | 1.74 |
Valuation Ratios
The PE ratio is -118.17 and the forward
PE ratio is -0.44.
X4 Pharmaceuticals's PEG ratio is
1.75.
PE Ratio | -118.17 |
Forward PE | -0.44 |
PS Ratio | 1730.67 |
Forward PS | 0.1 |
PB Ratio | 199.8 |
P/FCF Ratio | -33.72 |
PEG Ratio | 1.75 |
Financial Ratio History Enterprise Valuation
Currently the Enterprise Value (EV) is not available for X4 Pharmaceuticals.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.41,
with a Debt / Equity ratio of 3.53.
Current Ratio | 3.41 |
Quick Ratio | 3.33 |
Debt / Equity | 3.53 |
Debt / EBITDA | -2.83 |
Debt / FCF | -0.6 |
Interest Coverage | -4.15 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $17,881.12 |
Profits Per Employee | $-261,888.11 |
Employee Count | 143 |
Asset Turnover | 0.02 |
Inventory Turnover | 0.28 |
Taxes
Income Tax | 310K |
Effective Tax Rate | -0.83% |
Stock Price Statistics
The stock price has increased by -87.81% in the
last 52 weeks. The beta is 0.73, so X4 Pharmaceuticals's
price volatility has been higher than the market average.
Beta | 0.73 |
52-Week Price Change | -87.81% |
50-Day Moving Average | 4.98 |
200-Day Moving Average | 13.57 |
Relative Strength Index (RSI) | 50.47 |
Average Volume (20 Days) | 119,126 |
Income Statement
In the last 12 months, X4 Pharmaceuticals had revenue of 2.56M
and earned -37.45M
in profits. Earnings per share was -0.19.
Revenue | 2.56M |
Gross Profit | 1.76M |
Operating Income | -36.4M |
Net Income | -37.45M |
EBITDA | -27.58M |
EBIT | -28.37M |
Earnings Per Share (EPS) | -0.19 |
Full Income Statement Balance Sheet
The company has 55.7M in cash and 78.09M in
debt, giving a net cash position of -22.39M.
Cash & Cash Equivalents | 55.7M |
Total Debt | 78.09M |
Net Cash | -22.39M |
Retained Earnings | -515.36M |
Total Assets | 130.01M |
Working Capital | 69.81M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -130.9M
and capital expenditures -326K, giving a free cash flow of -131.23M.
Operating Cash Flow | -130.9M |
Capital Expenditures | -326K |
Free Cash Flow | -131.23M |
FCF Per Share | -0.65 |
Full Cash Flow Statement Margins
Gross margin is 68.83%, with operating and profit margins of -1423.58% and -1464.61%.
Gross Margin | 68.83% |
Operating Margin | -1423.58% |
Pretax Margin | -1452.48% |
Profit Margin | -1464.61% |
EBITDA Margin | -1078.45% |
EBIT Margin | -1423.58% |
FCF Margin | -5132.07% |